Format

Send to

Choose Destination
See comment in PubMed Commons below
Semin Cardiothorac Vasc Anesth. 2009 Jun;13(2):127-31. doi: 10.1177/1089253209338076.

Lessons learned in antifibrinolytic therapy: The BART trial.

Author information

  • 1London Health Sciences Center, University of Western Ontario, London, Ontario, Canada. John.Murkin@lhsc.on.ca

Abstract

Despite nearly 2 decades of published reports and clinical trials demonstrating the relative safety and efficacy of aprotinin in adult cardiac surgical patients at increased risk of bleeding-culminating in an official endorsement of the usage of aprotinin in such patients from both cardiac surgery and anesthesiology subspecialty committees-several more recent studies have raised profound concerns regarding the safety of aprotinin in these same patients. These studies and the implications thereof have ultimately resulted in the withdrawal of aprotinin from clinical usage internationally. This article will briefly review these developments with the hope of understanding how this abrupt turnabout took place and will attempt to understand how such events can be avoided in the future.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk